Greenwich LifeSciences clears FDA manufacturing hurdle for breast cancer vaccine
Greenwich LifeSciences (NASDAQ:GLSI) shares jumped Thursday morning after the clinical-stage biotech announced that the U.S. Food and Drug Administration (FDA) has approved the use of its first commercially manufactured lot of GP2 vials in the ongoing FLAMINGO-01 Phase III trial.












-640x358.jpg&w=3840&q=75)



-640x358.jpg&w=3840&q=75)
-640x358.jpg&w=3840&q=75)
-640x358.jpg&w=3840&q=75)

-640x358.jpg&w=3840&q=75)


